Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Regeneron Pharmaceuticals Inc
EIR
•Regeneron Pharmaceuticals Inc•October 18, 2019

Regeneron Pharmaceuticals Inc – FDA EIR, Oct 18, 2019

Record Details

An FDA inspection of Regeneron Pharmaceuticals Inc.'s Rensselaer, NY facility was conducted from October 9-18, 2019. The inspection focused on current Good Manufacturing Practices (cGMP) for non-sterile bulk and formulated biological drug substances, including Eylea, Kevzara, and Praluent. It was conducted under Compliance Program Guidance Manuals 7356.002M and 7356.021, emphasizing regulatory adherence to 21 CFR Parts 210/211, 600/601/610, and the Federal Food, Drug, and Cosmetic Act.

The main observation, noted on an FDA Form 483, highlighted the company's failure to adequately assess unexpected events potentially affecting the safety, purity, or potency of distributed biological products for regulatory reporting. Verbal discussions also addressed concerns about the timeliness and appropriateness of Corrective and Preventive Action (CAPA) implementation and proactive impact assessments for change controls. Specific issues identified included endotoxin recoveries linked to supplier-related contamination of a processing aid and the use of unsuitable transient sampling tubes for endotoxin testing. There was also an instance of abnormal cytotoxicity during viral screening, where initial documentation was incomplete.

Additionally, certain biological drug substance lots (Dupixent and Eylea) lacked final disposition by the Quality Assurance unit due to open investigations or quality decisions, with one regulatory assessment still pending. Regeneron management was advised to implement voluntary corrective and preventive actions. Failure to do so may result in further regulatory action, with the inspection's final classification pending a complete review of the report and the company's official response.

Company
Regeneron Pharmaceuticals Inc
Inspection date
October 18, 2019
Product type
biologics
Office
New York District Office
People
  • Mindy M. Chou
  • Patric C. Klotzbuecher
View Company Profile

ID · 2f21fa9c-603b-4c48-adf9-570ec85676b9

Violation Codes8
21 CFR 21021 CFR 21121 CFR 60021 CFR 60121 CFR 61021 CFR 31421 CFR 211.22(d)21 CFR 820.100

Full citation text and observation details available on the Dashboard.

Other documents for Regeneron Pharmaceuticals Inc
  • 483 - 2024-03-22March 22, 2024
  • 483 - 2021-10-25October 25, 2021
  • 483 - 2019-10-18October 18, 2019
  • EIR - 2018-06-08June 8, 2018
  • 483

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Regeneron Pharmaceuticals Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.